ARCHIMED, a leading investment firm focused on the healthcare sector, has acquired ExcellGene SA for an undisclosed amount. ExcellGene SA specializes in the development of high-yielding, GMP-ready cell lines and manufacturing processes for the production of biologics, biosimilars, and gene therapy products. This transaction marks a significant corporate acquisition, integrating ExcellGene SA's specialized expertise into ARCHIMED's portfolio.
With over 20 years of experience, ExcellGene SA has established itself as a trusted partner in cell line and process development. The company offers high-yielding CHO and HEK293 cell lines, crucial for expressing a wide range of proteins including bi-specific mAbs, Fc-fusions, and viral proteins. Its comprehensive services span process development, analytical methods, scale-up, tox-batches, and Master Cell Banking, supporting clients from project start to finish. This acquisition provides ARCHIMED with a robust platform in the critical area of biopharmaceutical manufacturing.
The strategic rationale behind this acquisition centers on expanding ARCHIMED's presence in the rapidly evolving biopharmaceutical and gene therapy markets. ExcellGene SA's proven track record and technical proficiency in developing specialized cell lines and manufacturing processes are highly valuable. By integrating ExcellGene SA, ARCHIMED aims to capitalize on the growing demand for high-quality, efficient production solutions for complex biologics. Expected synergies include accelerating ExcellGene SA's growth through ARCHIMED's strategic guidance and resources, potentially expanding its service offerings and market reach within the global healthcare landscape.
This acquisition underscores ARCHIMED's commitment to investing in innovative companies that enhance biopharmaceutical development and manufacturing capabilities. The combined entity is expected to continue supporting the advancement of new therapies by providing essential infrastructure and expertise, driving efficiency and quality in the production of cutting-edge medical treatments.